Seattle Genetics' Adcetris Positive in Durability Analysis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 25, 5:27PM CDT
Seattle Genetics, Inc. (SGEN) announced data from a two-year durability analysis of a phase I study on Adcetris for newly diagnosed mature T-cell lymphoma (MTCL).
Final Glance: Biotechnology companies
AP - Thu Sep 25, 5:02PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were down at the close of trading:
Acorda Skyrockets on $525M Civitas Therapeutics Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 25, 4:47PM CDT
Acorda is set to acquire privately-held biopharmaceutical company, Civitas Therapeutics.
Gilead Scores with TAF-based HIV Regimen, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 25, 4:20PM CDT
Gilead's (GILD) TAF- based STR performed well in two late-stage studies.
Genomic Health Upbeat on Strong International Performance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 25, 2:00PM CDT
Genomic Health (GHDX) is focused on delivering revenue growth through constant investment for higher adoption of its tests across three major cancers
Midday Glance: Biotechnology companies
AP - Thu Sep 25, 12:24PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 1 p.m.:
This Switch Could Make Gilead Sciences, Inc. Stock Billions
Brian Orelli, The Motley Fool - Motley Fool - Thu Sep 25, 11:01AM CDT
What's in a name? For Gilead Sciences , a few billion dollars. Tenofovir alafenamide and tenofovir disoproxil fumarate may sound similar enough (and also a mouthful), but tenofovir alafenamide, commonly referred to as TAF, is worth a heck of a...
Early Glance: Biotechnology companies
AP - Thu Sep 25, 10:40AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Stock Market News for September 25, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Thu Sep 25, 9:10AM CDT
Markets rebounded on Wednesday after taking losses in three straight sessions
Immunomedics Inc. (IMMU) Jumps: Stock Up 6.6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 25, 8:39AM CDT
Immunomedics Inc. (IMMU) was a big mover last session, as the company saw its shares rise almost 7% on the day.
The Best Biotech Stock for Your Growth Portfolio
Motley Fool Staff - Motley Fool - Thu Sep 25, 7:45AM CDT
For those willing to endure the inevitable price roller coaster, there's tremendous opportunity in hyper-growth biotech stocks. But you have to pick the best stocks if you're going to generate market-beating returns. So we asked each of our analysts...
The Medicines Patent Pool Adds New Sub-Licensing Agreements to Improve Access to Novel ARVs in Developing Countries
PR Newswire - Thu Sep 25, 6:59AM CDT
MPP signs sub-licences with six generic manufacturers for the development of Phase III drug Tenofovir Alafenamide
'Fast Money' Recap: What Market? The Focus Remains on Apple
at The Street - Thu Sep 25, 4:00AM CDT
The trading panel discussed how low the market can go and whether biotech stocks can continue to move higher.
Jim Cramer's 'Mad Money' Recap: Why You Can't Get Too Negative in This Market
at The Street - Wed Sep 24, 7:24PM CDT
Investors always need to be prepared for when common sense returns to the market, Cramer says.
Gilead reports good HIV trial
at Investor's Business Daily - Wed Sep 24, 5:30PM CDT
The biotech reported good late-stage trial data for its new HIV drug. The trial compared a standard combination of drugs in Gilead's (GILD) Stribild to a trial in which 1 of the components, sold individually as Viread, was replaced with tenofovir...
Novavax's Influenza Vaccine Study Shows Adjuvant Efficiency - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 24, 5:10PM CDT
Novavax, Inc. (NVAX) announced positive top-line data from a phase I/II study on influenza vaccine candidate, H7N9 VLP.
Gilead (GILD) Seeks Japanese Approval for HCV Combo Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 24, 5:00PM CDT
Gilead (GILD) is seeking Japanese approval for the combination of Sovaldi and ledipasvir .
Celgene's Otezla Label Expanded to Include Plaque Psoriasis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 24, 4:30PM CDT
Celgene's (CELG) Otezla gained FDA approval for plaque psoriasis.
Emergent BioSolutions Initiates Pivotal Study on BioThrax - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 24, 4:20PM CDT
Emergent BioSolutions (EBS) initiated a pivotal non-clinical study on BioThrax to support the licensure of the company's new modern facility, Building 55.
Watch for Gilead Sciences to Potentially Pullback After Gaining 3.10% Yesterday
Comtex SmarTrend(R) - Wed Sep 24, 3:37PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $106.02 to a high of $108.81. Yesterday, the shares gained 3.1%, which took the trading range above the 3-day high of $107.89 on volume of 14.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.